Cubist Pharmaceuticals
Cubist Pharmaceuticals was an American biopharmaceutical company that targeted pathogens like MRSA.
| Company type | Subsidiary (formerly: Public) |
|---|---|
Traded as | Nasdaq: CBST |
| Industry | Pharmaceuticals (Biopharmaceuticals & Biotherapeutics) |
| Founded | 1992 |
| Defunct | 2015 |
| Headquarters | Lexington, Massachusetts |
Key people | Robert J. Perez, President, CEO; |
| Products | Product Pipeline |
| Revenue | $926.4 million USD (2012) |
| Parent | Merck & Co. |
| Website | www.cubist.com |
. The company employed 638 people, mostly in Lexington, MA. On 8 December 2014, Merck & Co. acquired Cubist for $102 per share in cash ($8.4 billion).
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.